{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-006688","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2026-06-18T21:00:18+00:00","discovered_at":"2026-06-18T21:02:00.312010+00:00","generated_at":"2026-06-18T21:04:34.006390+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeOnc Technologies gets UAE IND approval for NEO212 brain cancer drug","bullets":["Department of Health – Abu Dhabi granted IND status for NEO212, an oral perillyl alcohol-temozolomide conjugate.","Phase 1 dose-escalation completed; 610 mg selected as recommended Phase 2 dose.","Early signs of durable disease stabilization seen in recurrent glioblastoma and brain metastases.","Company also submitted applications for NEO100 programs in UAE; awaiting decisions.","UAE approval follows U.S. FDA discussions on potential registrational pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-006688","json":"https://secwatch.observer/filing/0001829126-26-006688.json","markdown":"https://secwatch.observer/filing/0001829126-26-006688.md","text":"https://secwatch.observer/filing/0001829126-26-006688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626006688/0001829126-26-006688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626006688/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:04:34.006390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}